Opioid agonist therapy (OAT) has been available in a standard regime in the Czech Republic since 2000. Buprenorphine is the leading medication, while methadone is available only in a few specialised centres. There is an important leakage of buprenorphine onto the illicit market, and the majority of Czech opioid users are characterised by the misuse (and injecting) of diverted buprenorphine medications. Most prescribed buprenorphine for OAT is not covered by current national health insurance schemes, and patients have to pay considerable prices to afford their treatment. This affordability barrier together with limited accessibility is likely the leading factor of limited coverage of OAT and of recent stagnation in the number of patients in the official treatment programmes in the Czech Republic. It also encourages doctor shopping and the re-selling of parts of their medication at a higher price, which represents the main factor that drives the Czech illicit market for buprenorphine, but at the same time co-finances the medication of clients in official OAT programmes. Improving access to OAT by making it financially affordable is essential to further increase OAT coverage and is one of the factors that can reduce the illicit market with OAT medications.

Department of Addictology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

European Monitoring Centre for Drugs and Drug Addiction Lisbon Portugal

National Institute of Mental Health Klecany Czech Republic

National Monitoring Centre for Drugs and Addiction Office of the Government of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

United Nations Office on Drug and Crime . World Drug Report 2014. New York: United Nations; 2014.

European Monitoring Centre for Drugs and Drug Addiction . Trends and development. 2017. European Drug Report 2017. PubMed

Fischer B, Cruz MF, Rehm J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN) Can J Psychiatr. 2006;51(10):624–634. doi: 10.1177/070674370605101002. PubMed DOI

Donmall M, Jones A, Weston S, Davies L, Hayhurst KP, Millar T. The Drug Treatment Outcomes Research Study (DTORS): research design and baseline data. The Open Addiction Journal. 2012;5:1–11. doi: 10.2174/1874941001205010001. DOI

Best D, Gross S, Vingoe L, Witton J, Strang J. Dangerousness of drugs a guide to the risks and harms associated with substance misuse. London: National Addiction Centre and Department of Health; 2003.

Hedrich D, Pirona A, Wiessing L. From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe. Drugs: education, prevention and policy. 2008;15(6):503–517.

Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane database of systematic reviews. 2004:CD002207. PubMed

Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):1484–1492. doi: 10.1111/j.1360-0443.2008.02249.x. PubMed DOI

Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. 2008:CD004145. PubMed

Gowing L, Farrell MF, Bornemann R, Sullivan LE, Oral AR. The Cochrane database of systematic reviews. 2011. Substitution treatment of injecting opioid users for prevention of HIV infection; p. Cd004145. PubMed

Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abus Treat. 2005;28(4):321–329. doi: 10.1016/j.jsat.2005.02.007. PubMed DOI

Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;(10):CD004147. 10.1002/14651858.CD004147.pub4. PubMed

MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi: 10.1136/bmj.e5945. PubMed DOI PMC

Havnes I, Bukten A, Gossop M, Waal H, Stangeland P, Clausen T. Reductions in convictions for violent crime during opioid maintenance treatment: a longitudinal national cohort study. Drug Alcohol Depend. 2012;124(3):307–310. doi: 10.1016/j.drugalcdep.2012.02.005. PubMed DOI

Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug & Alcohol Dependence. 2016;161:1–8. doi: 10.1016/j.drugalcdep.2015.12.021. PubMed DOI

Abagiu Adrian Octavian, Cavar Zrinka, Dannon Pinhas, George Philip, Habrat Boguslaw, Mahomedy Zubeida, Popov Petr, Sarasvita Riza, Utami Diah Setia, Kastelic Andrej. Outcomes from the International Survey Informing Greater Insights in Opioid Dependence Treatment (INSIGHT) project. Drugs: Education, Prevention and Policy. 2014;21(6):440–450.

Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63. doi: 10.2105/AJPH.2015.302664. PubMed DOI PMC

Vranken MJM, Mantel-Teeuwisse AK, Junger S, Radbruch L, Scholten W, Lisman JA, et al. Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries. Addiction. 2017;112(6):1069–1076. doi: 10.1111/add.13755. PubMed DOI

European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2018 — Health and Social Responses 2018 [cited 2018 20 Oct]. Available from: http://www.emcdda.europa.eu/data/stats2018/hsr.

European Monitoring Centre for Drugs and Drug Addiction Perspectives on Drugs Strategies to prevent diversion of opioid substitution treatment medications Lisbon: EMCDDA; 2016. Available from: http://www.emcdda.europa.eu/topics/pods/preventing-diversion-of-opioid-substitution-treatment_en.

Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Patterns of prescription drug misuse among young injection drug users. J Urban Health. 2012;89(6):1004–1016. doi: 10.1007/s11524-012-9691-9. PubMed DOI PMC

Furst RT. Suboxone misuse along the opiate maintenance treatment pathway. J Addict Dis. 2013;32(1):53–67. doi: 10.1080/10550887.2012.759860. PubMed DOI

Bleckwenn M, Heister L, Weckbecker M, Weckbecker K, Mucke M. Misuse of substitution drugs in the substitution-based therapy. Eur Addict Res. 2016;22(6):322–328. doi: 10.1159/000448616. PubMed DOI

Carroll Jennifer J., Rich Josiah D., Green Traci C. The More Things Change. Journal of Addiction Medicine. 2018;12(6):459–465. doi: 10.1097/ADM.0000000000000436. PubMed DOI PMC

Alho H. Opioid agonist diversion in opioid-dependence treatment. In: el-Guebaly N, Carrà G, Galanter M, editors. Textbook of addiction treatment: international perspectives. Milano: Springer Milan; 2015. pp. 555–566.

Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, Mckeganey N, et al. The impact of misuse and diversion of opioid substitution treatment medicines: evidence review and expert consensus. Eur Addict Res. 2016;22:99–106. doi: 10.1159/000438988. PubMed DOI

Alho H, D’Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, et al. The extent of misuse and diversion of medication for agonist opioid treatment: a review and expert opinions. Heroin Addiction and Related Clinical Problems. 2015;17:25–34.

Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician’s perspective. Addiction. 2010;105:1531–1537. doi: 10.1111/j.1360-0443.2010.03014.x. PubMed DOI

Schulte B, Schmidt CS, Strada L, Gotzke C, Hiller P, Fischer B, et al. Non-prescribed use of opioid substitution medication: patterns and trends in sub-populations of opioid users in Germany. Int J Drug Policy. 2016;29:57–65. doi: 10.1016/j.drugpo.2015.12.024. PubMed DOI

European Monitoring Centre for Drugs and Drug Addiction . Statistical Bulletin 2017. Lisbon: EMCDDA; 2017.

Kalina K. Developing the system of drug services in the Czech Republic. J Drug Issues. 2007;37(1):181–204. doi: 10.1177/002204260703700109. DOI

Zábranský T, Csémy L, Gajdošíková H, Korčišová B, Kuda A, Miovský M, et al. Výroční zpráva o stavu a vývoji ve věcech drog v České republice za rok 2001. Praha: Úřad vlády ČR; 2002.

Ministerstvo zdravotnictví ČR . Věstník MZ ČR částka 3/2008 - Standard substituční léčby. Praha: Ministerstvo zdravotnictví ČR; 2008.

European Medicines Agency . EPAR summary for the public. Suboxone London: EMA; 2015.

Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105(4):709–718. doi: 10.1111/j.1360-0443.2009.02843.x. PubMed DOI PMC

Kelty E, Cumming C, Troeung L, Hulse G. Buprenorphine alone or with naloxone: which is safer? Journal of psychopharmacology (Oxford, England) 2018;32(3):344–352. doi: 10.1177/0269881118756015. PubMed DOI

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Tion Leštinová Z, Rous Z, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2015. Praha: Úřad vlády České republiky; 2016.

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Grolmusová L, Tion Leštinová Z, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2014. Praha: Úřad vlády České republiky; 2015.

Nechanská B, Mravčík V, Popov P. Zneužívání psychoaktivních léků v České republice. Idnetifikace zdrojů dat. Praha: Úřad vlády České republiky; 2012.

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Tion Leštinová Z, Rous Z, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2016. Praha: Úřad vlády České republiky; 2017.

Füleová A, Zónová J, Petrášová B. Výroční zpráva: incidence, prevalence, zdravotní dopady a trendy léčených uživatelů drog v České republice v roce 2014. Praha: Hygienická stanice hl. m. Prahy; 2015.

Mravčík V, Orlíková B. Překryv klientů mezi jednotlivými nízkoprahovými programy a zneužívání buprenorfinu v Praze. Adiktologie. 2007;7(1):13–20.

Mravčík V, Florián Z, Nečas V, Štolfa J. Infekční a další somatická komorbidita problémových uživatelů drog - výsledky průřezové studie s lékařským vyšetřením. Epidemiol Mikrobiol Imunol. 2016;1(65):56–62. PubMed

Malinovská J, Mravčík V. Problémové užívání opioidů mezi klienty nízkoprahových kontaktních center v Praze: dotazníkové šetření. Adiktologie Adiktologie 2017;17(4):262–271.

Malinovská J, Mravčík V. Vývoj problémového užívání opioidů na území České republiky: literární přehled. Adiktologie. 2017;17(4):282–291.

Švůgerová H. Spotřeba injekčního materiálu klienty pražských harm reduction služeb v závislosti na vzorcích užívání (Consumption of material for injection clients of Prague harm reduction services depending on use patterns) [Mgr.] Praha: Univerzita Karlova v Praze, 1. lékařská fakulta, obor adiktologie (MADI); 2015.

Větrovec M. Užívání buprenorfinu na pražské drogové scéně (Buprenorphine use in the Prague drug scene). Conference "Perspektivy Harm Reduction v Praze"; Prague: SANANIM; 2003.

Mravčík V, Grohmannová K, Chomynová P, Nečas V, Grolmusová L, Kiššová L, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2011. Praha: Úřad vlády ČR; 2012.

Mravčík V, Chomynová P, Grohmannová K, Nečas V, Grolmusová L, Kiššová L, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2013. Mravčík V, editor. Praha: Úřad vlády České republiky. ; 2014.

Řezníčková M, Nedvěd T. Zkušenosti terénních pracovníků s uživateli Subutexu na otevřené drogové scéně. Adiktologie. 2004;4(3 - supplementum):410–411.

Vranken MJM, Mantel-Teeuwisse AK, Jünger S, Radbruch L, Lisman J, Scholten W, et al. Legal barriers in accessing opioid medicines: results of the ATOME quick scan of national legislation of eastern European countries. J Pain Symptom Manag. 2014;48:1135–1144. doi: 10.1016/j.jpainsymman.2014.02.013. PubMed DOI

Mravčík V, Korčišová B, Lejčková P, Miovská L, Škrdlantová E, Petroš O, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2003. Praha: Úřad vlády České republiky; 2004.

Mravčík V, Rous Z, Tion Leštinová Z, Drbohlavová B, Chomynová P, Grohmannová K, et al. Výroční zpráva o hazardním hraní v České republice v roce 2014. Praha: Úřad vlády České republiky; 2015.

Gossop M. Treating drug misuse problems: evidence of effectiveness. London: National treatment Agency for Substance Misuse; 2006. p. 2009.

Schulte B, Thane K, Rehm J, Uchtenhagen A, Stöver H, Degkwitz P, et al. Review of the efficacy of drug treatment interventions in Europe: European Commission and Centre for interdisciplinary addiction research (ZIS) of the Hamburg University. 2008.

Fareed A, Casarella J, Roberts M, Sleboda M, Amar R, Vayalapalli S, et al. High dose versus moderate dose methadone maintenance: is there a better outcome? J Addict Dis. 2009;28(4):399–405. doi: 10.1080/10550880903183042. PubMed DOI

Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict. 2010;19(6):557–568. doi: 10.1111/j.1521-0391.2010.00086.x. PubMed DOI

Fareed A, Vayalapalli S, Casarella J, Drexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse. 2012;38(2):155–160. doi: 10.3109/00952990.2011.643988. PubMed DOI

Český statistický úřad. Průměrná hrubá měsíční mzda zaměstnanců v národním hospodářství podle ekonomické činnosti (sekce CZ-NACE) - z ročního zjišťování Prague: Český statistický úřad; 2018 [cited 2019 6 Oct]. Available from: https://www.czso.cz/documents/10180/60664312/1100251807.pdf/957401d8-cfe1-4f37-b748-80fe29f7d536?version.

Bičáková O. Zvýšení minimální mzdy od 1. ledna 2016. Národní pojištění. 2015(11). Available from: https://www.cssz.cz/cz/casopis-narodni-pojisteni/archiv-vydanych-cisel/2015-11-03-zvyseni-minimalni-mzdy-od-1-ledna-2016.htm.

Gluzová J. Vzorce užívání buprenorfinu u klintů Terénního programu SANANIM (Patterns of buprenorphine use among clients of Outreach Programme SANANIM) [Bc.]. Praha: Univerzita Karlova v Praze, 1. lékařská fakulta, obor adiktologie (BADI); 2014.

Launonen E, Wallace I, Kotovirta E, Alho H, Simojoki K. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients. Drug Alcohol Depend. 2016;162:227–235. doi: 10.1016/j.drugalcdep.2016.03.017. PubMed DOI

Knudsen HK, Roman PM. Financial factors and the implementation of medications for treating opioid use disorders. J Addict Med. 2012;6(4):280–286. doi: 10.1097/ADM.0b013e318262a97a. PubMed DOI PMC

Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health affairs (Project Hope) 2013;32(8):1462–1469. doi: 10.1377/hlthaff.2012.0846. PubMed DOI PMC

Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574. doi: 10.1146/annurev-publhealth-031914-122957. PubMed DOI

Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Current Drug Abuse Review. 2011;4:28–41. doi: 10.2174/1874473711104010028. PubMed DOI PMC

Pompidou Group Opioid Agonist Treatment. Guiding principles for legislation and regulations. Expert group on the regulatory framework for the treatment of opioid dependence syndrome and the prescription of opioid agonist medicines. Strasbourg: Council of Europe; 2017.

Simojoki K, Alho H. Finnish experience with buprenorphine-naloxone combination (Suboxone®): survey evaluations with intravenous drug users. Heroin Addiction and Related Clinical Problems. 2008;10:33–36.

Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway

Large variations in all-cause and overdose mortality among >13,000 patients in and out of opioid maintenance treatment in different settings: a comparative registry linkage study

Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study